Amylase-Producing IgG Kappa Type Multiple Myeloma.
- Author:
Kyoung Cheon KIM
1
;
Hong Seok LEE
;
Yong Seok JANG
;
Won Sik LEE
;
Hong Suk SON
Author Information
1. Department of Internal Medicine, Sunlin Hospital, Handong University, Pohang, Korea. shs7436@dsmc.or.kr
- Publication Type:Case Report
- Keywords:
Hyperamylasemia;
Multiple myeloma;
Chemotherapy
- MeSH:
Abnormal Karyotype;
Amylases;
Bone Marrow;
Bone Marrow Cells;
Cytogenetics;
Drug Therapy;
Female;
Humans;
Hyperamylasemia;
Immunoglobulin G*;
Immunoglobulins;
Karyotype;
Melphalan;
Middle Aged;
Multiple Myeloma*;
Plasma Cells;
Prednisolone;
Prognosis
- From:Korean Journal of Hematology
2002;37(2):158-160
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Amylase-producing multiple myeloma is a rare disorder and has poor prognosis. Its characteristics are elevation of salivary type amylase, extensive extramedullary spread, extensive bone destruction, shorter survival time, and abnormal karyotype. Recently, we have experienced a case of amylase-producing IgG kappa type multiple myeloma in a 63-year-old woman. On admission, serum and urine amylase was 8,450U/L and 169,710U/L, 85% and 86% of which was determined to be the salivary type, respectively. The other cause of hyperamylasemia had not been detected. The presence of immunoglobulin and amylase in the myeloma cells was demonstrated immunohistochemically. Bone marrow aspiration smear revealed 59.1% plasma cells. The cytogenetic study of bone marrow cell showed normal karyotype. The patient died 3 months after chemotherapy with melphalan and prednisolone.
